Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sionna TherapeuticsSION +3.02%12 Cash-to-Debt is 26.15 as of Jun. 2026, which is 2% below its 10-year median of 26.67. GuruFocus rates SION with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,397 Biotechnology companies, Sionna Therapeutics ranks better than 65.43% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sionna Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 26.15.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Sionna Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Sionna Therapeutics's Cash-to-Debt or its related term are showing as below:
SION'
s Cash-to-Debt Range Over the Past 10 Years
Min: 3.68 Med: 26.67 Max: No Debt
Current: 26.15
During the past 4 years, Sionna Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 3.68. And the median was 26.67.
SION's Cash-to-Debt is ranked better than 65.43% of 1397
companies
in the Biotechnology industry
Industry Median: 6.78
vs SION: 26.15
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Sionna Therapeutics Cash-to-Debt Related Terms
Sionna Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Sionna Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Sionna Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sionna Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sionna Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Sionna Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sionna Therapeutics (SION) has a Cash-to-Debt of 26.15 as of Jun. 2026. This is near median its historical median of 26.67. Over the past decade, Sionna Therapeutics' Cash-to-Debt has ranged from 3.68 to 10,000.00. According to the industry distribution chart, Sionna Therapeutics ranks #483 out of 1397 companies in the Biotechnology industry, placing it in the top 34.6%.
Is Sionna Therapeutics' Cash-to-Debt too high?
Sionna Therapeutics' current Cash-to-Debt of 26.15 is near median its 10-year median of 26.67. Over the past 10 years, this metric has ranged from a low of 3.68 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.78. Sionna Therapeutics' value of 26.15 is 285.7% above this industry median. Based on the distribution chart, Sionna Therapeutics ranks #483 out of 1397 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sionna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sionna Therapeutics' Cash-to-Debt compare to ACIU and SRZN?
According to the Biotechnology industry distribution chart, Sionna Therapeutics ranks #483 out of 1397 companies for Cash-to-Debt. This puts Sionna Therapeutics in the upper half of its industry. The industry median Cash-to-Debt is 6.78. Sionna Therapeutics' value of 26.15 is 285.7% above this benchmark. Historically, Sionna Therapeutics' own Cash-to-Debt has ranged from 3.68 to 10,000.00 over the past decade. While the company's 10-year median is 26.67 vs. the industry median of 6.78, Sionna Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.78, based on 1,397 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sionna Therapeutics's current Cash-to-Debt of 26.15 is 285.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sionna Therapeutics's current Cash-to-Debt is 26.15, which is near median its own 10-year median of 26.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sionna Therapeutics stock overvalued right now?
Sionna Therapeutics (SION) has a current Cash-to-Debt of 26.15. The current Cash-to-Debt is 26.15, which is near median its 10-year median of 26.67 and 285.7% above the Biotechnology industry median of 6.78. Sionna Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Sionna Therapeutics (SION), the current Cash-to-Debt is 26.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
12GF Score
Get the complete analysis for SION
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SION has been successfully added to your 
